


Provided for non-commercial research and education use.
Not for reproduction, distribution or commercial use.



This article appeared in a journal published by Elsevier. The attached copy is furnished to the author for internal non-commercial research and education use, including for instruction at the authors institution and sharing with colleagues.

Other uses, including reproduction and distribution, or selling or licensing copies, or posting to personal, institutional or third party websites are prohibited.

In most cases authors are permitted to post their version of the article (e.g. in Word or Tex form) to their personal website or institutional repository. Authors requiring further information regarding Elsevier's archiving and manuscript policies are encouraged to visit:

<http://www.elsevier.com/copyright>



Contents lists available at SciVerse ScienceDirect

Advanced Drug Delivery Reviews

journal homepage: www.elsevier.com/locate/addrHydrogels for delivery of bioactive agents: A historical perspective[☆]Sang Cheon Lee^a, Il Keun Kwon^a, Kinam Park^{a,b,c,*}^a Kyung Hee University, School of Dentistry, Department of Maxillofacial Biomedical Engineering and Institute of Oral Biology, Seoul, Republic of Korea^b Purdue University, Departments of Biomedical Engineering, West Lafayette, IN, USA^c Purdue University, Department of Pharmaceutics, West Lafayette, IN, USA

ARTICLE INFO

Article history:

Accepted 26 July 2012

Available online 18 August 2012

Keywords:

Hydrogels

Smart hydrogels

Self-regulated drug delivery

Clinical applications

Mimicking natural systems

ABSTRACT

Since 1960 when the history of modern hydrogels began significant progress has been made in the field of controlled drug delivery. In particular, recent advances in the so-called smart hydrogels have made it possible to design highly sophisticated formulations, e.g., self-regulated drug delivery systems. Despite intensive efforts, clinical applications of smart hydrogels have been limited. Smart hydrogels need to be even smarter to execute functions necessary for achieving desired clinical functions. It is necessary to develop novel hydrogels that meet the requirements of the intended, specific applications, rather than finding applications of newly developed hydrogels. Furthermore, developing smarter hydrogels that can mimic natural systems is necessary, but the fundamental differences between natural and synthetic systems need to be understood. Such understanding will allow us to develop novel hydrogels with the new, multiple functions that we are looking for.

© 2012 Elsevier B.V. All rights reserved.

Contents

1. Research on hydrogels	17
2. Hydrogels for drug delivery	18
3. Self-regulated drug delivery systems	18
4. Current and future research on hydrogels	19
5. Mimicking natural systems	20
Acknowledgments	20
References	20

1. Research on hydrogels

The number of references published under the research topic of “hydrogel” has increased exponentially during the last decade. According to SciFinder[®], the first reference on hydrogel appeared in 1894. Although the hydrogels described during that time period was a colloidal gel of inorganic salts, which are not exactly the same type of hydrogels we are dealing with nowadays, the use of the word “hydrogel” in as early as 1894 is very interesting. Since then, the term “hydrogel” was used to describe a 3-dimensional network of hydrophilic natural polymers and gums, in which the network is formed chemically or

physically. The hydrogel of current understanding for biological use was first developed by Wichterle and Lim in 1960 [1]. Although the usefulness of hydrogels in biomedical applications was recognized, the number of publications on hydrogels was still under 100/year until 1974. As shown in Fig. 1A, the number of references on hydrogel took off in the middle of 1970s and grew exponentially 20 years later. Since 2000, the yearly publication surpassed 1000, and the number is close to 5000 for the last two years. Fig. 1B describes relative numbers of publications under the topics of “drug delivery,” “nanotechnology,” and “smart hydrogels”. The “drug delivery” term was further refined into “protein” and “gene” for estimating the relative research efforts on protein delivery and gene delivery. As shown in Fig. 1B, the number of publications on smart hydrogels is about the same as that of gene delivery. On the other hand, research on protein delivery has been much more active due to the longer history of protein drugs resulting from advances in genetic engineering. The number of references on nanotechnology skyrocketed from the middle of 2000s, reflecting the research trend in the last decade.

[☆] This review is part of the *Advanced Drug Delivery Reviews* theme issue on “25th Anniversary issue—Advanced Drug Delivery: Perspectives and Prospects”.

* Corresponding author at: Purdue University, Departments of Biomedical Engineering and Pharmaceutics, 206 S. Martin Jischke Drive, West Lafayette, IN 47907, USA. Tel.: +1 765 494 7759.

E-mail address: kpark@purdue.edu (K. Park).




Fig. 1. The number of references published under the research topic of “hydrogel” in SciFinder®. The total number of papers on hydrogel from 1950 to 2011 is 43,764. Of these, 8554 references were on the topic of drug delivery. In the drug delivery topic, the search for subtopics on protein and gene resulted in 1674 and 284 references, respectively. Of the 43,764 hydrogel references, the search for topics on nanotechnology and smart hydrogels resulted in 1246 and 130 references, respectively.

2. Hydrogels for drug delivery

Analysis of the references on drug delivery by the index terms resulted in more than 1000 different terms. The most widely used index terms include pharmaceutical hydrogels, dissolution, physical swelling, and controlled release. Despite a large number of references related to hydrogel-based drug delivery systems, however, the actual number of hydrogel-based drug delivery systems or devices approved by the Food and Drug Administration (FDA) is extremely small. The clinically used hydrogel-based drug delivery systems or devices are mostly for contact lenses, intraocular lenses, wound dressing, surgical tissue sealant, anti-adhesive of tissues, hydrogel tissue expander, and transdermal patch containing hydrogels for drug delivery.

Research on hydrogels for drug delivery has been focused on developing advanced drug delivery systems, such as self-regulated insulin delivery systems and artificial pancreas. These systems are based on the so-called smart hydrogels which respond to a minute change in environmental conditions with a large change in physicochemical

properties, degradation, sol–gel phase transition, and shape transformation [2]. In comparison with smart hydrogels, ordinary hydrogels undergo only the swelling–deswelling process depending on the availability of water in the environment. It is the additional properties over the basic swelling–deswelling property that makes a hydrogel smart. The environmental factors, also referred to as external stimuli, can be physical (temperature, electricity, magnetic field, ultrasound, and pressure), chemical (pH, ion type, ionic strength, and solvent) and biological (enzyme, antibody, and glucose).

Applications of smart hydrogels have been divided into four broad areas, such as drug delivery, bioseparation, biosensor, and tissue engineering. Here we focus on drug delivery. As pointed out above, we need to understand the reasons for the lower number of hydrogel products that are in clinical use, despite the rather extensive research activities. We need to ask ourselves why we do what we do, i.e., why do we do research on hydrogels? There may be various valid answers, and research on hydrogels does not always have to lead to clinically useful products, as long as scientific advances are made. But, one of the ultimate goals of researchers in the drug delivery field is to provide new drug delivery systems or devices treating diseases and helping patients. In this sense, it is time to examine why translational research has not been as successful as expected.

Hydrogel properties need to be optimized for developing advanced drug delivery systems. The properties to be optimized are safety, biodegradability, drug loading capacity, and control on drug release kinetics. The safety of any materials is the first concern that has to be answered. Unless a hydrogel material has been used for extended periods of time without any serious side effect, its safety has to be proven before clinical use. This is not a trivial matter, and for this reason, hydrogel materials that have been previously used in FDA-approved products are widely chosen. For implantable devices, biodegradable hydrogels are preferred because it does not require surgical removal. For example, histrelin hydrogel implant, which is implanted just under the skin of children's inner upper arm to release luteinizing hormone-releasing hormone (LHRH) for a year, requires surgical removal [3]. It is made of the same material as a soft contact lens, which does not degrade, and thus, it has to be removed after a year by a surgical procedure.

Controlling drug loading and subsequent release is also critical for intended applications. For implantable drug delivery systems, sustained drug release for months, is required. Yet, most hydrogel formulations cannot release a loaded drug for such a long period of time. This is mainly due to the nature of hydrogels which swell in the presence of water, resulting in fast drug release. Many papers on smart hydrogels have been published [4–7]. Smart hydrogel drug delivery systems include enzyme-sensitive hydrogel nanoparticles, magnetic hydrogels, drug-sensitive hydrogels, and hydrogels for dual protein delivery. The duration of drug release in most studies is usually limited to a few days maximum. For practical applications the duration of drug delivery needs to be much longer, especially when the hydrogel system is to be implanted. The point of using smart hydrogels is not just to make a new, unique formulation. Rather, it should be to make better formulations than the existing ones in their functions and properties, e.g., release for extended periods of time with controllable release kinetics or self-regulated release.

3. Self-regulated drug delivery systems

One of the holy grails of controlled drug delivery is self-regulated insulin delivery systems. Insulin delivery is not like any other drug delivery where a sustained, long-term release can achieve an intended goal. Insulin release has to occur at the right time in the right amount. Insulin delivery starts with measuring the glucose concentration in the blood or in an environment in equilibrium with that of the blood. Once the glucose level increases, the right amount of insulin has to be released to lower the glucose concentration. Once the




Fig. 2. A general setup of a feedback-controlled self-regulated drug delivery system and requirements for glucose-dependent insulin delivery system.

glucose level is brought down to the normal level, insulin release should be turned off to avoid hypoglycemia. Thus, controlling the timing, speed, and amount of released insulin is critical. Fig. 2 shows a schematic diagram of a self-regulated drug release system using insulin delivery as an example.

There have been extensive studies on self-regulated insulin delivery hydrogel systems. Since the presence of a glucose sensing ability is essential, most of the hydrogel systems utilize a glucose-sensitive moiety to control the swelling (for faster release of insulin) and deswelling (for retarded insulin release). Commonly used glucose sensors are glucose oxidase [8], hydrogen peroxide [9], lectin [10], and boronic acid [11] embedded inside hydrogels that undergo sol-gel phase transition. The key to the successful implementation of these systems is the repeatability, and thus, self-oscillating property is critical [12,13]. Yet, all glucose sensitive hydrogels show gradually diminishing sensitivity toward glucose as the environmental glucose level changes. As shown in Fig. 2, reversibility and repeatability are critical, and it will be necessary to build a hydrogel system possessing robust repeatability, in addition to other requirements. Currently, there is no hydrogel system that meets all the requirements described in Fig. 2. If and when we can achieve self-regulated insulin delivery

for clinical application, we will be able to handle drug delivery for any disease.

4. Current and future research on hydrogels

As mentioned above, the number of FDA-approved clinical products based on hydrogels is rather small. There may be many reasons for this, but one of them is that the current approach of hydrogel research for drug delivery is not quite in sync with formulation development. The current approach is to synthesize new smart hydrogels having new properties. Once a new hydrogel is synthesized, then suitable applications are sought out for the hydrogel. Since the new hydrogel was not prepared for any particular application in mind, whatever potential application is identified, there is unavoidable mismatch between the hydrogel properties and applications. This mismatch makes it very difficult to produce any clinically useful product. A common view has been that clinical product development has to be done in the industry and the scientists in academia should focus on basic research, although the definition of basic research is often not clear. In any case, the focus of current trend in the hydrogel research is simply making novel hydrogels. To the FDA, the novel




Fig. 3. The current approaches in hydrogel research and its application for developing clinical products in comparison with the suggested future efforts on hydrogel research.




Fig. 4. Comparison of evolution of natural systems and synthetic systems mimicking the natural systems. From Ref. [14].

properties of a novel hydrogel do not make any difference, i.e., a novel hydrogel is just another unknown material. For approval of any product for clinical applications, the FDA requires safety and efficacy of the product.

Novel hydrogels are not necessarily better for clinical applications. If one of the goals of conducting hydrogel research is to develop clinically useful formulations, the current research practice has to be modified. The current and suggested future hydrogel research is shown in Fig. 3. An ideal research approach is to identify the target application first, and then develop a new hydrogel specifically tailor-made for the application. This requires clear understanding of the physiological requirements and the design of a new hydrogel that can meet the requirements. This approach will clearly allow faster translation to clinical formulations.

5. Mimicking natural systems

One approach of designing a successful clinical formulation is to mimic natural systems. After all, a holy grail of making a self-regulated insulin delivery system is just to mimic the pancreas, a natural system. Mimicking natural systems, however, is not as easy as it sounds, because there are fundamental differences in the way that natural systems are formed and the way that synthetic systems are created, as shown in Fig. 4 [14]. In natural systems, evolution occurs to increase the efficacy, and therefore become simpler, for the survival, and it fulfills biological needs. All these occur at the molecular level, and so the natural systems truly deal with nanosystems. On the other hand, all synthetic systems are made by miniaturizing the existing systems, rather than assembling from the molecular building blocks, and then seeking for clinical efficacy. The top-down approach is not able to produce exactly the same object made by bottom-up approaches. For this reason, mimicking natural systems appears to produce objects that may look similar to natural systems, but it will not result in exactly the same functions as those that natural systems have.

One of the critical properties that hydrogels need to have to mimic natural systems is the speed. Natural polymer gels with fast responses include sensitive plants (e.g., *Minosa pudica*), nonmuscle cells, muscle contractile systems, and bacterial flagellar motors [15]. These natural systems have evolved in a cumulative fashion through thousands of years. Deconstructing the systems to understand the rate-limiting steps in fast responsive (or reflexive) systems is necessary for preparing synthetic systems [14]. Understanding this limitation that synthetic systems inspired by natural systems will not have the same functions is important. Such an understanding elicits new ideas to solve the problems at hand with more practical approaches. It is time to discuss how to build the hydrogel systems that can really provide functions we need to meet the clinical needs. Obviously the difficulty to overcome is enormous, but the first step to overcome it is to recognize it.

Acknowledgments

This study was supported in part by NIH through grants CA129287 and GM095879, and Showalter Research Trust Fund.

References

- [1] O. Wichterle, D. Lim, Hydrophilic gels for biological use, *Nature* 185 (1960) 117–118.
- [2] Y. Qiu, K. Park, Environmentally-sensitive polymer hydrogels, *Adv. Drug Deliv. Rev.* 53 (2001) 321–339.
- [3] A.I. Limited, Histrelin hydrogel implant—valera: histrelin implant, LHRH-hydrogel implant, RL 0903, SPD 424, *Drugs R&D* 6 (2005) 53–55.
- [4] C.L. Bayer, N.A. Peppas, Advances in cognitive, conductive and responsive delivery systems, *J. Control. Release* 132 (2008) 216–221.
- [5] C. He, S.W. Kim, D.S. Lee, In situ gelling stimuli-sensitive block copolymer hydrogels for drug delivery, *J. Control. Release* 127 (2008) 189–207.
- [6] R. Cheng, F. Feng, F. Meng, C. Deng, J. Feijen, Z. Zhong, Glutathione-responsive nano-vehicles as a promising platform for targeted intracellular drug and gene delivery, *J. Control. Release* 152 (2011) 2–12.
- [7] M. Delcea, H. Möhwald, A.G. Skirtach, Stimuli-responsive LbL capsules and nanoshells for drug delivery, *Adv. Drug Deliv. Rev.* 63 (2011) 730–747.
- [8] S.I. Kang, Y.H. Bae, A sulfonamide based glucose-responsive hydrogel with covalently immobilized glucose oxidase and catalase, *J. Control. Release* 86 (2003) 115–121.
- [9] T. Uchiyama, Y. Kiritoshi, J. Watanabe, K. Ishihara, Degradation of phospholipid polymer hydrogel by hydrogen peroxide aiming at insulin release device, *Biomaterials* 24 (2003) 5183–5190.
- [10] J.J. Kim, K. Park, Modulated insulin delivery from glucose-sensitive hydrogel dosage forms, *J. Control. Release* 77 (2001) 39–47.
- [11] D. Shiino, Y. Murata, A. Kubo, Y.J. Kim, K. Kataoka, Y. Koyama, A. Kikuchi, M. Yokoyama, Y. Sakurai, T. Okano, Amine containing phenylboronic acid gel for glucose-responsive insulin release under physiological pH, *J. Control. Release* 37 (1995) 269–276.
- [12] G.P. Misra, R.A. Siegel, New mode of drug delivery: long term autonomous rhythmic hormone release across a hydrogel membrane, *J. Control. Release* 81 (2002) 1–6.
- [13] R. Yoshida, T. Sakai, Y. Hara, S. Maeda, S. Hashimoto, D. Suzuki, Y. Murase, Self-oscillating gel as novel biomimetic materials, *J. Control. Release* 140 (2009) 186–193.
- [14] K. Park, N. Yui, R.J. MRSNY, A perspective on current and future synthetic reflexive systems, in: N. Yui, R.J. MRSNY, K. Park (Eds.), *Reflexive Polymers and Hydrogels. Understanding and Designing Fast Responsive Polymeric Systems*, CRC Press, Boca Raton, 2000, pp. 427–437.
- [15] N. Baek, K. Park, Natural polymer gels with fast responses, in: N. Yui, R.J. MRSNY, K. Park (Eds.), *Reflexive Polymers and Hydrogels. Understanding and Designing Fast Responsive Polymeric Systems*, CRC Press, Boca Raton, 2000, pp. 85–96.